ANNEX 1 QUESTIONNAIRE EXPERT SURVEY



Annex 1. Questionnaire expert survey

[pic]

[pic] [pic]

Questionnaire concerning

national population surveys on drug use

Prof. Dr Tom Decorte

Prof. Dr Dimitri Mortelmans

Sabine De Moor

Julie Tieberghien

This project is commissioned by the Belgian Science Policy and supported by the European Monitoring Centre for Drugs and Drug Addiction

Introduction

Although Belgium puts in a great effort to gain insight into the epidemiologic situation concerning drug use (e.g. among the school-going youth), Belgium has no extended research tradition in relation to the prevalence of drug use. So far, the prevalence of drug use within the general Belgian population has never been studied. The aim of this research is a feasibility study of a repetitive survey among the general population. The feasibility study is commissioned by the Belgian Science Policy ([1]) and carried out by the Institute for Social Drug Research (Prof. Dr Tom Decorte, University of Ghent) and the Research Centre for Longitudinal and Life Course Studies (Prof. Dr Dimitri Mortelmans, University of Antwerp).

Most European countries have already conducted one or more general population surveys, but there are important intrinsic and methodological-technical differences. Our research covers a detailed comparison of prevalence studies in other European countries, and includes a limited cognitive test of the included items with a view to the implementation of such study in Belgium. The feasibility study is composed of five foci: intrinsic focus (which concepts, prevalence indicators, characteristics of drug use, socio-demographic characteristics, lifestyle indicators and attitudes are to be included in the instrument), methodological focus (data collection method, sample size (sample frame, over representations, weighting, size), frequency of the survey, etc.), comparative focus (comparability with national and international surveys), financial focus (general costs in relation to the choices of data collection and length of the questionnaire) and valorisation focus (feasibility and desirability of the distribution mode of the findings).

In the first phase of this study we studied the international recommendations regarding measurement of drug use in the general population (EMCDDA, WHO, etc.) Furthermore, a meta-analysis of all existing prevalence studies in Europe is made. The meta-analysis of general population surveys covers a detailed comparison of items and question modules, methods and designs, used in prevalence studies in other European countries, and the evaluation of strengths, restrictions, preconditions and costs of these studies. A first draft of this meta-analysis is included in the appendix.

All experts responsible for national population surveys in the European Union are invited to complete this questionnaire. We would like to ask you some questions about several aspects of the design and the organisation of general population surveys on drugs in your country. The questionnaire, developed in close cooperation with the EMCDDA, gives special attention to the legitimations for choices that were made and to (reasons for) deviations from European guidelines, and also to the impact of general social, cultural and political practices in a country on the design of the study and specific implications and limitations of the national context. The questionnaire also focuses on the comparability and valorization of the data. Next to gaining insight in the experiences and know-how of the national experts, your answers may help us to complete and up-date the overview of general populations surveys previously made by the EMCDDA ([2]).

As a result, a proposal of a ‘best fit’ design for a Belgian population survey on drug use will be developed and tested. This must enable Belgian policymakers to decide whether or not and how to implement a national prevalence study.

The final report will be available in Dutch and English at the end of 2008.

How to fill in the questionnaire?

The questions are related to the ‘Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze in Italia’ administered in the years 2001, 2003 and 2005.

The questionnaire contains four parts. First, some general questions are asked, followed by detailed questions about intrinsic (A.) and methodological aspects (B.) in order to complete the EMCDDA overview (2001). The questionnaire ends with some questions about financial (C.) and valorisation aspects (D.). It takes about 40 minutes to complete this questionnaire.

The questionnaire can be completed in the electronic version (recommended) or on a printed version. We kindly ask you to return the questionnaire by e-mail, postal service or fax at the latest before 19 May 2008. The contact information can be found at the end of this questionnaire.

Open-ended questions may be answered by typing/writing the answer in the provided space. In addition, there are several multiple choice questions. These questions can be answered by clicking/ticking on the box () besides the correct answer.

Given the importance of and usefulness of this meta-analysis of general population surveys on drugs for many experts around Europe, we hope for your participation and express our gratitude in advance.

Yours truly,

Prof. Dr Tom Decorte

Prof. Dr Dimitri Mortelmans

Sabine De Moor

Julie Tieberghien

A. General questions

The following questions are only related to ‘Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze in Italia’ administered in the year 2005.

1. The survey has been carried out at:

National level only

Other, please specify

|      |

2. What was the type of survey:

Single: survey dealt with drugs (and/or alcohol, tobacco and pharmaceuticals) only

Please specify why it was decided to develop a ‘single’ survey (and why, for example, the survey was not set up by ‘piggybacking’ if there was an opportunity).

|      |

Multi: questions about drug use were part of a survey with a wider scope (piggybacking)

Please specify the type of survey:

Health survey

Crime survey

Other, please specify

|      |

What was/were the reason(s) for piggybacking?

Lower cost

Obtaining information about related items (e.g. health, crime)

Other, please specify

|      |

Did your research team evaluate the impact of the context (e.g. health, crime) on prevalence rates? If yes, could you elaborate on the reflections made?

|      |

3. Describe the main objectives and research questions the survey wanted to answer:

(a)

|      |

(b)

|      |

(c)

|      |

(d)

|      |

4. Who was the commissioner of the survey (the authority or institute that initiated and commissioned the survey?)

The government (e.g. Ministry of Health)

Please specify which ministry or department

|      |

An academic institution (e.g. university)

Please specify which faculty or research centre

|      |

A private/commercial company (e.g. research agency)

Please specify which

|      |

5. Who was the responsible agent of the survey (the institute or organisation that was in charge for the organisation and analysis of the survey)?

The government (e.g. Ministry of Health)

Please specify which ministry or department

|      |

An academic institution (e.g. university)

Please specify which faculty or research centre

|      |

A private/commercial company (e.g. research agency)

Please specify which

|      |

6. Frequency of the survey:

Each year (annually)

Every       years (example: every 2 years, 3 years, 4 years, etc.)

Every       to       years (example: every 3 to 4 years)

Other, please specify

|      |

7. Can you specify the reason(s) why the research team chose to conduct the survey as frequently as indicated in the previous question?

|      |

8. Year(s) in which a similar survey was carried out in your country in the past:

|      |

9. Year(s) in which a similar survey will be carried out in the future:

|      |

10. What was the data collection method?

Mail

Telephone

Computer-assisted telephone interviewing (CATI)

Not computer assisted

Face-to-face

Computer-assisted personal interviewing (CAPI)

Computer-assisted self interviewing (CASI)

Pen and paper

Web-based survey

Other ( please specify

|      |

11. How do you motivate the choice for this mode of interviewing?

|      |

12. Is the questionnaire compatible with the recommendations of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)?

No

Yes

How do you assess the comparability of your questionnaire to the European Model Questionnaire (EMQ)?

Fully comparable to the EMQ

Highly comparable to the EMQ

Moderately comparable to the EMQ

Little comparable to the EMQ

Not comparable to the EMQ

Please specify to what extent the questionnaire deviates from the EMCDDA recommendations

Concerning the intrinsic aspects (time frames: LTP, LYP, TMP; frequency and age of first use; number of illicit drugs; inclusion of new products; inclusion/exclusion of a dummy drug …)

Please specify how:

|      |

Please specify why:

|      |

Concerning the methodological aspects

(The EMCDDA is not very prescriptive on this point. However, the following aspects are recommended: probabilistic sample, regular surveys, maintain methodology and sample, a big enough sample and results should be reproducible …)

Please specify how:

|      |

Please specify why:

|      |

13. Is the questionnaire compatible with the recommendations of the World Health Organization (WHO)?

No

Yes

Please specify to what extent the questionnaire deviates from the recommendations

Concerning the intrinsic aspects (number of illicit drugs, inclusion of new products, inclusion/exclusion of a dummy drug …)

Please specify how:

|      |

Please specify why:

|      |

Concerning the methodological aspects (sample size, sampling frame, data collection method …)

Please specify how:

|      |

Please specify why:

|      |

14. Have you also checked the European School Survey Project on Alcohol and other Drugs (ESPAD)?

No

Yes ( Can you explain why?

|      |

15. Have you also checked the Health Behaviour in School-aged Children (HBSC)?

No

Yes ( Can you explain why?

|      |

16. Does the questionnaire take into consideration other recommendations?

No

Yes

Please specify the recommendations (name, responsible agents and content):

|      |

17. Is the consumption of other substances than illicit substances included in the survey?

No

Yes, please specify:

Alcohol

Tobacco

Pharmaceuticals/medicines

None

Other, please specify

|      |

18. Why (or why not) does the questionnaire include licit substances?

|      |

19. How many questions about illicit substances are included in the questionnaire?

      questions

20. When comparing the most recent survey with previous surveys, the number of questions about illicit substances is …

(If this was the first drug survey, please go to question 22)

Staying equal

Increasing

Please specify why:

|      |

Decreasing

Please specify why:

|      |

21. When comparing the most recent survey to the previous surveys, were there any adaptations made?

No adaptations

Adaptations

Please specify:

Concerning the intrinsic aspects (number of illicit drugs, inclusion of new products, inclusion/exclusion of a dummy drug …)

|      |

Concerning the methodological aspects (sample size, sampling frame, data collection method …)

|      |

Concerning the financial aspects (changes in the budget, changes in the financial sources …)

|      |

Concerning the valorisation (the language of the report, the spread of the results)

|      |

22. Does the design of the questionnaire contain a well-considered sequence of questions (or question modules)?

No

Yes

Please specify:

|      |

23. In general, if you consider the next survey, will any intrinsic adaptations (inclusion/exclusion of items, questions or question modules …) be made?

No

Yes

Please specify which adaptations and why:

|      |

24. Has there ever been conducted a pilot test concerning these intrinsic adaptations?

No

Yes

Please specify the pilot test

|      |

25. In general, if you consider the next survey, will any methodological adaptations (other data collection method, larger/smaller sample size …) be introduced?

No

Yes

Please specify which adaptations and why:

|      |

26. Has there ever been conducted a pilot test concerning these methodological adaptations?

No

Yes

Please specify the pilot test

|      |

27. Language(s) in which the survey was carried out:

|      |

B. Detailed questions

The following detailed questions are about intrinsic and methodological aspects of ‘Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze in Italia’ administered in the years 2001, 2003 and 2005.

Methodological aspects

1. What was the purpose of analysis of the data of the 2001 survey?

Descriptive (primarily descriptions of current situations or trends)

Causal inference (more cross-sectional association between drug use and other factors like the respondent’s characteristics)

Explanatory (systematic explanation of drug prevalence) based on theoretical assumptions and empirical observations (e.g. Urbanisation)

2. What was the purpose of analysis of the data of the 2003 survey?

Descriptive

Causal inference

Explanatory

3. What was the purpose of analysis of the data of the 2005 survey?

Descriptive

Causal inference

Explanatory

4. The upper age limit of the target population was different in every wave of the survey. Could you please explain this choice?

|Country |Year |Target population |

|Italy |2001 |15–44 years |

| |2003 |15–54 years |

| |2005 |15–64 years |

|      |

5. In drug surveys, sometimes specific groups are excluded from the target population. Were there any groups excluded from the target population in the different Italian surveys?

No ( go to question 6

Yes ( please fill in question 5.a and 5.b

5.a. Which groups were excluded? Please indicate the excluded groups in the table below with the corresponding number(s)

|Country |Year |Groups excluded from the target population |

|Italy |2001 |      |

| |2003 |      |

| |2005 |      |

1. Non-native speakers

2. Institutionalised people (prisoners, hospitalised persons ...)

3. Homeless people

4. Other ( please specify in the table

5.b. Why were these groups excluded from the target population?

Groups are not covered by the sampling frame

Groups are difficult to reach

Other, please specify

|      |

6. In drug surveys, over-sampling is often done. Did the Italian surveys contain (some) boost sample(s)?

No ( go to question 7

Yes ( please fill in question 6.a and 6.b.

6.a. Which groups were over-sampled? Please indicate the over-sampled groups in the table below with the corresponding number(s) and specify the excluded groups in the table.

|Country |Year |Over-sampling |

|Italy |2001 |      |

| |2003 |      |

| |2005 |      |

1. Youngsters

2. Inner-city areas/urban areas

3. Ethnic groups

4. Other groups

5. No groups excluded

6.b. Over-sampling is often done in groups with higher expected prevalences. This is a common and recommended practice for a more efficient use of the sample. Was this also the reason for over-sampling in your study/studies?

Yes, higher expected prevalences in the over-sampled groups

No, other reason ( please specify

|      |

7. Was the sampling frame in 2001 also the register of the resident population?

Yes ( go to the next question

No ( please fill in the correct answer in the table below.

|Country |Year |Sampling frame |Sampling method(s) |

|Italy |2001 |      |Stratified random sampling from resident |

| | | |population |

| |2003 |Register of the resident |Stratified random sampling from resident |

| | |population |population |

| |2005 |Register of the resident |Multistage stratified random sample |

| | |population | |

8. The following questions are about the weighting of the survey data.

8.a. Were the data of the 2001 survey weighted?

No

Yes

Please specify why:

|      |

Please specify how (by which variables):

|      |

8.b. Were the data of the 2003 survey weighted?

No

Yes

Please specify why:

|      |

Please specify how (by which variables):

|      |

8.c. Were the data of the 2005 survey weighted?

No

Yes

Please specify why:

|      |

Please specify how (by which variables):

|      |

9. Regarding the sample characteristics, could you please complete the table below?

|Country |Year |Estimated size of |Original sample size (N) |Net response |Response rate (%) |

| | |target population |(sample size minus frame | | |

| | |(millions) |errors) | | |

|Italy |2001 |      |      |      |      |

| |2003 |      |      |      |      |

| |2005 |      |      |      |      |

10. In general, how was the size of the sample determined?

|      |

11. The next questions are about the time scope of the 2001 study.

11.a. What was the time scope (in months) of the whole study?

|      |

11.b. What was the time scope (in months) of the data collection?

|      |

11.c. What was the average duration (in minutes) of the administration of one single questionnaire?

|      |

12. The next questions are about the time scope of the 2003 study.

12.a. What was the time scope (in months) of the whole study?

|      |

12.b. What was the time scope (in months) of the data collection?

|      |

12.c. What was the average duration (in minutes) of the administration of one single questionnaire?

|      |

13. The next questions are about the time scope of the 2005 study.

13.a. What was the time scope (in months) of the whole study?

|      |

13.b. What was the time scope (in months) of the data collection?

|      |

13.c. What was the average duration (in minutes) of the administration of one single questionnaire?

|      |

14. Are there any remarkable (dis)advantages of the chosen methodology of the questionnaire (concerning sampling frame, sample size, data collection method …)?

|      |

Intrinsic aspects

These questions are about the intrinsic aspects of the survey, such as prevalence measures, frequency measures, the number of illicit drugs included, etc. Unless otherwise mentioned, please complete the tables below with ‘yes’ or ‘no’. ‘Yes’ stands for: item is included in the survey; ‘no’ means that the item is not included.

1. The following questions concern the inclusion of illicit drugs.

1.a. Can you please indicate which illicit drugs are included in the surveys by completing the table with ‘yes’ or ‘no’?

|Country |Year |Illicit drugs |

| |

1.c. The EMQ includes cannabis, LSD, heroin, cocaine and amphetamines. If your survey included other drugs, what was the reason for adding those other drugs?

|      |

1.d. Was there a dummy drug included in the survey?

No ( go to question 2

Yes ( please fill in the questions 1.e. ( 1.f.

1.e. What was the name of the bogus drug and why was that name chosen?

|      |

1.f. How useful is the inclusion of a dummy drug according to you?

|      |

2. Can you please indicate which licit drugs are included in the surveys by completing the table with ‘yes’ or ‘no’?

|Country |Year |Licit drugs |

| | |Alcohol |Tobacco |Pharmaceuticals |

|Italy |2001 |      |      |      |

| |2003 |      |      |      |

| |2005 |      |      |      |

2.a. Which pharmaceuticals were included? Can you please specify why those pharmaceuticals?

|      |

2.b. Did the surveys include different forms of alcohol (e.g. beer, wine …) consumption?

No ( go to question 2.c.

Yes ( please specify which modalities/forms

|      |

2.c. Did the surveys include different forms of tobacco (e.g. cigars, cigarettes …) consumption?

No ( go to question 3

Yes ( please specify which modalities/forms

|      |

3. The following questions consider the inclusion of prevalence measures of illicit drug use.

3.a. Please complete the table below by indicating ‘all’, ‘some’ or ‘no’. ‘All’ refers to the inclusion of a particular prevalence measure for all illicit drugs included. ‘Some’ indicates the inclusion of a particular prevalence measures for some illicit drugs. ‘No’ means that the prevalence measure was not included in the study.

|Country |Year |Illicit drugs |

| | |LTP |LYP |LMP |

|Italy |2001 |      |      |      |

| |2003 |      |      |      |

| |2005 |      |      |      |

3.b. If you have indicated the inclusion of a particular prevalence measure for some illicit drugs, can you please specify which drugs?

|      |

4. Are prevalence measures of licit drug use included in the surveys?

No ( go to the next question

Yes ( please fill in the table below by indicating ‘yes’ or ‘no’

|Country |Year |Alcohol |Tobacco |Pharmaceuticals |

| | |LTP |

| | |LTF |LYF |LMF |

|Italy |2001 |      |      |      |

| |2003 |      |      |      |

| |2005 |      |      |      |

5.b. If you have indicated the inclusion of a particular frequency measure for some illicit drugs, can you please specify which drugs?

|      |

5.c. Did the surveys include frequency measures of alcohol and tobacco?

No ( go to question 5.d.

Yes ( please fill in the table below by indicating ‘Yes’ (included) or ‘No’ (not included)

|Country |Year |Alcohol |Tobacco |

| | |LTF |

| | |LTF |LYF |LMF |Other |

|Italy |2001 |      |      |      |      |

| |2003 |      |      |      |      |

| |2005 |      |      |      |      |

6. These questions concern the inclusion of the item quantity of use.

6.a. Did the surveys include questions on quantity of illicit drug use?

No ( go to question 6.b.

Yes ( please fill in the table below by indicating ‘Yes’ (included) or ‘No’ (not included)

|Country |Year |Illicit drugs |

| | |cannabis |

| | |Alcohol |Tobacco |Pharmaceuticals |

|Italy |2001 |      |      |      |

| |2003 |      |      |      |

| |2005 |      |      |      |

7. Please complete the table below concerning other items related to illicit drug use by indicating ‘All’ (for all drugs), ‘Some’ (for some drugs) or ‘No’ (not included).

|Country |Year |Age of onset |Multiple |Injecting |Availability |Health effects of |

| | | |drug use | | |use |

| |2003 |      |      |      |      |      |

| |2005 |      |      |      |      |      |

7.a. Did the surveys include ‘age of onset’ for all illicit drugs or some illicit drugs?

All ( go to question 7.b.

Some ( please specify for which drugs

|      |

7.b. Did the surveys include questions about ‘injecting’?

No ( go to question 7.d.

Yes ( Please specify how intravenous use was measured. Which questions were included?

|      |

7.c. How useful is the inclusion of injecting as a variable according to you?

|      |

7.d. Did the surveys include questions about ‘availability’?

No ( go to question 7.g.

Yes ( please specify how the availability of drugs was measured

‘Been offered a particular (illicit) drug’

‘The ease or the difficulty to obtain a particular drug within 24 hours’

Other, please specify which

|      |

7.e. Why was this interpretation of availability chosen?

|      |

7.f. Of which drugs is the availability measured?

All ( go to question 7.g.

Some ( please specify for which drugs

|      |

7.g. Did the surveys include questions about ‘multiple drug use’?

No ( go to question 7.h.

Yes ( Please specify how multiple drug use was measured. Which questions were included?

|      |

7.h. Did the surveys include questions about ‘health effects of use’?

No ( go to question 8.

Yes ( Please specify how health effects of use were measured. Which questions were included?

|      |

8. The following tables concern the socio-demographic and socio-economic attributes of the respondent.

8.a. Please indicate in the table which socio-demographic attributes were included in the surveys by indicating ‘yes’ or ‘no’.

|Country |Year |Socio-demographic |

| | |Age |Gender |Household type |Ethnicity |

|Italy |2001 |      |      |      |      |

| |2003 |      |      |      |      |

| |2005 |      |      |      |      |

8.b. Did the surveys include questions about ‘ethnicity’?

No ( go to question 8.d.

Yes ( Please specify how ethnicity was measured. Which questions and answer categories were included?

|      |

8.c. How useful is the inclusion of ethnicity as a variable according to you?

|      |

8.d. Did the surveys include questions about ‘religion’?

No ( go to question 8.f.

Yes ( Please specify how religion was measured. Which questions and answer categories were included?

|      |

8.e. How useful is the inclusion of religion as a variable according to you?

|      |

8.f. Please indicate in the table which socio-economic attributes were included in the surveys by indicating ‘yes’ or ‘no’.

|Country |Year |Socio-economic |

| | |Level of education |Employment status |Income |

|Italy |2001 |      |      |      |

| |2003 |      |      |      |

| |2005 |      |      |      |

8.g. Did the surveys include questions about income?

No ( go to question 9

Yes ( Please specify how income was measured. Which questions and answer categories were included?

|      |

9. The following tables concern the questions about environment.

9.a. Please indicate in the table which items were included in the surveys by indicating ‘yes’ or ‘no’.

|Country |Year |Residential characteristics |Confrontation |

| | | |Personal 'knowing drug |Neighbourhood 'seeing drug |

| | | |users' ([3]) |users' |

|Italy |2001 |      |      |      |

| |2003 |      |      |      |

| |2005 |      |      |      |

9.b. Did the surveys include questions about residential characteristics?

No ( go to question 10

Yes ( Please specify how residential characteristics were measured. Which questions and answer categories were included?

|      |

10. Regarding the inclusion of lifestyle items, did the surveys include questions about entertainment or social contacts?

No ( go to question 11

Yes ( please complete the table below by indicating ‘Yes’ (included) or ‘No’ (not included)

|Country |Year |Entertainment |Social contacts |

|Italy |2001 |      |      |

| |2003 |      |      |

| |2005 |      |      |

10.a. Did the surveys include questions about entertainment?

No ( go to question 10.b.

Yes ( Please specify how this was measured. Which questions and answer categories were included?

|      |

10.b. Did the surveys include questions about social contacts?

No ( go to question 11

Yes ( Please specify how this was measured. Which questions and answer categories were included?

|      |

11. Please complete the table below regarding attitudes and opinions by indicating ‘Yes’ (included) or ‘No’ (not included).

|Country |Year |Risk perception |Opinion |Opinion on drug policy |

| | |Health |Social |Drug addicts |Legal status |Interventions |

| |2003 |      |      |      |      |      |

| |2005 |      |      |      |      |      |

11.a. Did the surveys include questions about risk perception?

No ( go to question 11.b.

Yes ( Please specify how this was measured. Which questions and answer categories were included?

|      |

11.b. Did the surveys include questions about opinions on drug addicts?

No ( go to question 11.c.

Yes ( Please specify how this was measured. Which questions and answer categories were included?

|      |

11.c. Did the surveys include questions about opinions on drug policy?

No ( go to the next question

Yes ( Please specify how this was measured. Which questions and answer categories were included?

|      |

C. Financial aspects

In this part, some questions about finances and budgets will be asked. The questions are only related to ‘Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze in Italia’ administered in the year 2005.

We know that this information may be delicate. Therefore, we want to give you the following option:

Yes, the given financial data may be integrated in the report of the Belgian feasibility study.

No, the given financial data may not be integrated in the report of the Belgian feasibility study. The released information may only be used to contextualise the Belgian data.

1. Who was/were responsible for the financial support of the national population survey?

The government

At the national level, please specify which:

|      |

At the regional level, please specify which:

|      |

An academic institution (e.g. university)

Please specify which:

|      |

A private/commercial company (e.g. research agency)

Please specify which:

|      |

At any other level

Please specify which:

|      |

2. What was the budget (in euro) of those different levels?

The government

At the national level, please specify how much:

|      |

At the regional level, please specify how much:

|      |

An academic institution (e.g. university)

Please specify how much:

|      |

A private/commercial company (e.g. research agency)

Please specify how much:

|      |

At any other level

Please specify how much:

|      |

3. The next questions are about the budget and costs of the study.

3.a. What were the costs (in euro) for the data collection?

|      |

3.b. What was the average cost (in euro) per single interview?

|      |

3.c. What were the costs (in euro) for the data analysis and the data set?

|      |

3.d. What was the total cost (in euro) for the whole study (instrument development, sampling process, data analysis ... )?

|      |

4. Did any restrictions have to be made in the survey design due to an inadequate budget?

No

Yes, please specify which

|      |

5. The next questions are about the requirements concerning staff.

5.a. How many FTE (full-time equivalents) senior researchers (PhD level) have worked on the survey project? How long have they worked on this? For example: two FTE for a time period of nine months.

Number of FTE:      

Time period (in months):      

5.b. How many FTE junior researchers (Master level) have worked on the survey project? How long have they worked on this?

Number of FTE:      

Time period (in months):      

5.c. How many FTE interviewers have worked on the survey project? How long have they worked on this?

Number of FTE:      

Time period (in months):      

5.d. How many other FTE (secretary ...) have worked on the survey project? How long have they worked on this?

Number of FTE:      

Time period (in months):      

D. Valorisation aspects

In this part, some questions about the valorisation and the spread of the results will be asked. The questions are only related to ‘Relazione Annuale al Parlamento sullo Stato delle Tossicodipendenze in Italia’ administered in the year 2005.

1. Which steps are undertaken to improve the accessibility of the results of the national population survey? (except for the National report to the EMCDDA)

Report accessible on the Internet

Please specify the Internet site(s):

|      |

Report published in a book

Please give the title(s) of the book(s):

|      |

Publication in scientific articles

Please specify the title(s) of the articles:

|      |

Presentation of the data on (inter)national conferences/seminars

Please specify the name(s) and date(s) of the conferences/seminars:

|      |

The accessibility of results through electronic database(s)

Please specify the name of the database(s):

|      |

Who has access to this database(s)?

|      |

How can the database(s) be consulted?

|      |

Other, please specify:

|      |

2. Could you please give us a list of (other) publications in English or French related to the survey?

|      |

3. In which language(s) are the results presented (the EMCDDA summary does not count as full results)?

In the native language(s):      

In English

Both (English and native language)

Other, please specify

|      |

4. How long after finishing the survey, the full results can be consulted? (number of months/years)

|      |

5. Are the anonymized micro data accessible for analysis by persons other than the data manager(s)?

No

Yes

Who has access to the anonymized micro data?

Academics

Politicians

Students

The general public

Other, please specify

|      |

How are the micro data distributed?

By the researchers themselves

By a data archive, please specify

|      |

Other, please specify

|      |

What is the procedure to obtain the micro data?

(the conditions below are based on those of the Sociological Data Archive (SDA) archive of the Czech Republic)

Data sets can be downloaded from the Internet

Data sets can be downloaded from the Internet after registration

Data sets are available after signing an agreement with the standard conditions for using data sets and their documentation

Data sets are available after signing an agreement with the standard and other specific conditions, according to the terms set out by the depositor

Data sets are available only with the written permission of the depositor

Data sets are available only for specific institutions or persons

Other, please specify

|      |

Is there free access to the data?

Always free access

Never free access

Only free access in certain conditions

Please specify these conditions:

|      |

Are there any obligations for users to inform the researchers about the use of the data set and publications?

No

Yes, please specify

|      |

In which format(s) are the data distributed?

SPSS

SAS

ASCII

Other, please specify

|      |

Which predefined/preconstructed variables are available in the database (e.g. in the European Social Survey (ESS), a social variable ‘social class’ is constructed)?

|      |

Is the privacy of the respondents guaranteed?

No

Yes, please specify how

|      |

Can you estimate the current number of users of the data set?

|      |

THANK YOU FOR ANSWERING THE QUESTIONS.

Please return this questionnaire to:

Ms Julie Tieberghien

Ghent University

Institute for Social Drug Research

Universiteitstraat, 4

B-9000 Ghent

Belgium

Tel. (office): +32 92648451

Tel. (mobile): +32 479885065

Fax : +32 92648495

E-mail: Julie.Tieberghien@UGent.be

-----------------------

([1]) For more information about the research project, see the website:

([2]) EMCDDA (2002), Handbook for surveys on drug use among the general population, Final report, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.

.

([3]) This item refers to whether personal acquaintance with users of an illicit drug (e.g. family, friends, colleagues) was recorded. There is relevance with some warming-up questions, such like ‘Have you ever heard of …?’

-----------------------

[pic]

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download